Interleukin-17A derived from mast cells contributes to fibrosis in gastric cancer with peritoneal dissemination
Open Access
- 2 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 24 (1), 31-44
- https://doi.org/10.1007/s10120-020-01092-2
Abstract
Objectives Interleukin-17A (IL-17A) is pro-inflammatory cytokine and acts as profibrotic factor in the fibrosis of various organs. Fibrosis tumor-like peritoneal dissemination of gastric cancer interferes with drug delivery and immune cell infiltration because of its high internal pressure. In this study, we examined the relationship between IL-17A and tissue fibrosis in peritoneal dissemination and elucidated the mechanism of fibrosis induced by IL-17A using human peritoneal mesothelial cells (HPMCs) and a mouse xenograft model. Methods Seventy gastric cancer patients with peritoneal dissemination were evaluated. The correlation between IL-17A and fibrosis was examined by immunofluorescence and immunohistochemistry. A fibrosis tumor model was developed based on subcutaneous transplantation of co-cultured cells (HPMCs and human gastric cancer cell line MKN-45) into the dorsal side of nude mice. Mice were subsequently treated with or without IL-17A. We also examined the effect of IL-17A on HPMCs in vitro. Results There was a significant correlation between IL-17A expression, the number of mast cell tryptase (MCT)-positive cells, and the degree of fibrosis (r = 0.417, P < 0.01). In the mouse model, IL-17A enhanced tumor progression and fibrosis. HPMCs treated with IL-17A revealed changes to a spindle-like morphology, decreased E-cadherin expression, and increased α-SMA expression through STAT3 phosphorylation. Moreover, HPMCs treated with IL-17A showed increased migration. Conclusions IL-17A derived from mast cells contributes to tumor fibrosis in peritoneal dissemination of gastric cancer. Inhibiting degranulation of mast cells might be a promising treatment strategy to control organ fibrosis.Keywords
Funding Information
- KAKENHI (16K10494)
This publication has 42 references indexed in Scilit:
- Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosisCancer Chemotherapy and Pharmacology, 2013
- The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancerInternational Journal of Oncology, 2012
- Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathwayThe Journal of Experimental Medicine, 2009
- The basics of epithelial-mesenchymal transitionJCI Insight, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironmentBlood, 2008
- Mast cells are an essential hematopoietic component for polyp developmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Mast cells and eosinophils in invasive breast carcinomaBMC Cancer, 2007
- Gastric cancer treated in 1991 in Japan: data analysis of nationwide registryGastric Cancer, 2006